Aug 24 (Reuters) - Aequus Pharmaceuticals Inc AQS.V
* Aequus Pharmaceuticals Inc - received positive feedback from FDA to pursue abbreviated 505(b)(2) clinical pathway for co's AQS1301
* Aequus Pharmaceuticals- upon review of pre-IND submission, FDA agreed AQS1301 is suitable candidate for 505(b)(2) regulatory pathway for approval in U.S.